Patient Enrollment in Global Ph 3 Trial of Buparlisib (AN2025) + Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC completed December 11, 2023
FDA Grants Priority Review of Supplemental BLA for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer December 11, 2023
Both FDA Fast Track and Breakthrough Therapy Designation for Cretostimogene Grenadenorepvec in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer December 11, 2023
TAR-200 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer December 11, 2023
FDA Accepts for Priority Review Application for Opdivo + Cisplatin-Based Chemo for the 1L Treatment of Adult Patients with Unresectable/Metastatic urothelial carcinoma December 11, 2023
FDA granted “Fast-Track” Designation for Novel Armed Nanocell Drug Conjugate (ANDC) Pancreatic Cancer Therapeutic EDV (EnGeneIC Dream Vector) December 11, 2023
Abecma Approved in Earlier Lines of Therapy for Patients with R/R Multiple Myeloma in Japan December 11, 2023
KEYLYNK-008 Trial of KEYTRUDA + LYNPARZA for Patients With Metastatic Squamous NSCLC to Stop for Futility December 11, 2023
FAILED TRIAL: Ph 3 LEAP-001 Trial of KEYTRUDA + LENVIMA as 1L Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma did not meet primary dual endpoints December 11, 2023
Encouraging Initial Data from Randomized SELECT-AML-1 Ph 2 Trial of Tamibarotene in Combination with Venetoclax and Azacitidine Announced December 11, 2023
Interim Data from Ph 1b Trial of Vepdegestrant in Combination with IBRANCE Announced December 11, 2023
Sarclisa Ph 3 trial met primary endpoint of PFS in patients with newly diagnosed multiple myeloma not eligible for transplant December 11, 2023
Interim Data from Ph 1b/2 Clinical Trial of Nana-val in Patients with EBV+ve Solid Tumors Show Confirmed Tumor Responses at Higher Dose Levels December 11, 2023
Interim Data Presented from Two Ongoing Ph 2 Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation December 11, 2023
FAILED TRIAL: CERPASS Clinical Trial of RP1 + cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma did not meet primary endpoints December 11, 2023
Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma December 11, 2023
Ph 3 CheckMate -8HW Trial of Opdivo + Yervoy vs Chemo in MSI-H or MRD Metastatic CRC Meets Primary endpoint December 11, 2023
Latest Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence in patients with early breast cancer; supports regulatory submissions December 11, 2023
Inavolisib combination reduces the risk of disease progression by 57% in people with advanced HR+ve, HER2-neg breast cancer with a PIK3CA mutation December 11, 2023
Kadcyla shows significant OS benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment December 11, 2023
Findings from Ph 2 KeyVibe-002 Trial of Coformulation of Vibostolimab and Pembrolizumab in Previously Treated Patients with mNSCLC Announced December 11, 2023
New Positive Interim Data from Dose Escalation and Ph 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients Announced December 11, 2023
New Data Show Durable Response Following Treatment with ADSTILADRIN® (nadofaragene firadenovec-vncg) December 11, 2023
Successful Completion and Interim Results of Ph 1 Study of HC-5404 in Solid Tumors announced December 11, 2023
